novavax
participate
upcoming
conferences
gaithersburg
globe
newswire
novavax
nasdaq
nvax
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
participate
four
upcoming
investor
industry
conferences
novavax
vaccine
candidate
expected
discussed
conference
maryland
life
sciences
bio
innovation
conference
date
monday
october
time
et
panel
title
discussion
pandemic
risk
mitigation
focus
preparation
resiliency
three
maryland
biotech
leaders
discuss
prepare
unforeseen
needed
pivot
future
panelist
john
trizzino
executive
vice
president
chief
business
officer
chief
financial
officer
attend
click
register
guggenheim
first
annual
vaccines
infectious
diseases
conference
date
monday
october
time
et
participation
fireside
chat
investor
meetings
novavax
participants
gregory
glenn
president
research
development
john
trizzino
executive
vice
president
chief
business
officer
chief
financial
officer
webcast
replay
session
available
within
hours
events
page
company
website
days
following
event
goldman
sachs
virtual
event
inoculating
recovery
discussion
vaccines
treatments
testing
economy
date
thursday
october
time
et
panel
title
vaccines
approaching
light
end
tunnel
panelist
gregory
glenn
president
research
development
event
open
goldman
sachs
clients
biohealth
capital
region
forum
date
monday
october
time
et
panel
title
strengths
region
combatting
infectious
disease
panelist
vivek
shinde
vice
president
clinical
development
attend
click
register
vaccine
candidate
engineered
genetic
sequence
virus
causes
disease
created
using
novavax
recombinant
nanoparticle
technology
generate
antigen
derived
coronavirus
spike
protein
contains
novavax
patented
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
contains
purified
protein
antigen
replicate
cause
preclinical
trials
demonstrated
indication
antibodies
block
binding
spike
protein
receptors
targeted
virus
critical
aspect
effective
vaccine
protection
phase
portion
phase
clinical
trial
generally
elicited
robust
antibody
responses
numerically
superior
seen
human
convalescent
sera
also
evaluated
phase
trial
uk
two
ongoing
phase
studies
began
august
phase
trial
south
africa
phase
continuation
australia
novavax
secured
billion
funding
global
coronavirus
vaccine
program
including
million
funding
coalition
epidemic
preparedness
innovations
cepi
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
undergoing
clinical
trials
vaccine
candidate
virus
causes
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
vaccine
candidates
incorporate
novavax
proprietary
adjuvant
order
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
information
visit
connect
us
twitter
linkedin
contacts
investors
silvia
taylor
erika
trahan
ir
media
brandzone
kogs
communication
edna
kaplan
kaplan
